Almirall reports increased net sales growth in 9-month 2023 financial results

Key takeaways:

• Almirall’s net sales for the 9-month mark of 2023 have reached 674.6 million euros.
• The company reports robust business growth due to the 15.9% increase of sales in Europe.

Almirall announced its 9-month 2023 financial results, which included a year-on-year net sales increase of 6.4% due to its European sales, according to a company press release.

“Almirall has delivered a consistently strong operational performance throughout the first nine months of 2023, and we are pleased to modestly upgrade our net sales guidance for the year,” Carlos Gallardo Piqué, chairman and CEO of Almirall, said in the press release.

The company reported business growth of 15.9% in Europe. Additionally, Almirall’s net sales for the 9-month mark reached 674.6 million euros. Total earnings before interest, taxes, depreciation and amortization were 138.2 million euros, according to the release, which was a 5.6% decrease compared with the same period last year.

Growth drivers that contributed to Almirall’s performance include steady, year-on-year sale increases of Ilumetri and Wynzora for the treatment of psoriasis and Klisyri for the treatment of actinic keratosis in Europe.

Almirall continues to prepare for the launch of lebrikizumab for the treatment of atopic dermatitis. After receiving a positive opinion from the Committee for Medicinal Products for Human Use for the marketing authorization of lebrikizumab in September, the company is expecting an imminent response concerning the drug’s approval in Europe.

In August, Almirall also submitted a supplementary new drug application to the FDA for Klisyri for the treatment of actinic keratosis, and the company expects approval and a subsequent launch in the second half of 2024.